Targeted therapies for NSCLC
While chemotherapy is a systemic treatment, targeted therapies attack specific genetic mutations in the cancer or target processes that allow the cancer to grow.
Learn about targeted therapies for NSCLC
Targeted Therapies for Non-small Cell Lung Cancer (American Cancer Society)
Targeted Therapies for Lung Cancer (Lung Cancer Alliance)
Advances in Targeted Therapies Tutorial (National Cancer Institute)
Targeted therapies used to treat NSCLC
Currently, three targeted therapies are approved to treat NSCLC. Tarceva (erlotinib) and Xalkori (crizotinib) are in pill form, while Avastin (bevacizumab) is administered through an IV. Targeted therapies have side effects, however they are often less severe than those from chemotherapy. Targeted therapies may be given alone or particularly in the case of Avastin, with chemotherapy. Targeted therapies are sometimes used as maintenace therapy.
Avastin (bevacizumab)
Avastin (Chemocare)
Bevacizumab (National Cancer Institute)
Avastin.com (Genentech)
Tarceva (erlotinib)
Tarceva (Chemocare)
Erlotinib (National Cancer Institute)
Xalkori (crizotinib)
Xalkori capsules (Chemocare)
Crizotinib (Xalkori) (National Cancer Institute)
Xalkori.com (Pfizer)
See also:
Tests and procedures to identify treatment options
Targeted therapies side effects
